944547-46-0
| 中文名稱 | 944547-46-0 |
|---|---|
| 中文同義詞 | C-MYC抑制劑(MYCRO 3);化合物MYCRO-3;5-(7-(氯二氟甲基)-5-(呋喃-2-基)吡唑并[1,5-A]嘧啶-2-甲酰胺基)-1-苯基-1H-吡唑-4-羧酸乙酯;化合物MYCRO-3,10 MM DMSO 溶液;Mycro 3試劑;Mycro 3 ,S0249;Mycro 3試劑 |
| 英文名稱 | Mycro3 |
| 英文同義詞 | Mycro3;ethyl 5-[[7-[chloro(difluoro)methyl]-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidine-2-carbonyl]amino]-1-phenylpyrazole-4-carboxylate;Mycro-3, >98%;1H-Pyrazole-4-carboxylic acid, 5-[[[7-(chlorodifluoromethyl)-5-(2-furanyl)pyrazolo[1,5-a]pyrimidin-2-yl]carbonyl]amino]-1-phenyl-, ethyl ester;Ethyl 5-(7-(chlorodifluoromethyl)-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamido)-1-phenyl-1H-pyrazole-4-carboxylate;dimerization,Mycro 3,pancreatic,inhibit,adenocarcinoma,ductal,c-Myc,Inhibitor,PDA,Autophagy,Mycro3,MAX,Myc;ethyl 5-[7-(chlorodifluoromethyl)-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidine-2-amido]-1-phenyl-1H-pyrazole-4-carboxylate;Mycro 3, 10 mM in DMSO |
| CAS號 | 944547-46-0 |
| 分子式 | C24H17ClF2N6O4 |
| 分子量 | 526.88 |
| EINECS號 | |
| 相關(guān)類別 | 細(xì)胞生物學(xué)試劑 |
| Mol文件 | 944547-46-0.mol |
| 結(jié)構(gòu)式 |  |
944547-46-0 性質(zhì)
| 密度 | 1.53±0.1 g/cm3(Predicted) |
|---|---|
| 儲存條件 | Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | 二甲基亞砜：≥100mg/mL（189.80mM） |
| 酸度系數(shù)(pKa) | 6.95±0.46(Predicted) |
| 形態(tài) | 固體 |
| 顏色 | 淺黃至黃色 |
| InChIKey | YPPNLSKYXDXQGD-UHFFFAOYSA-N |
| SMILES | N1(C2=CC=CC=C2)C(NC(C2C=C3N(N=2)C(C(Cl)(F)F)=CC(C2=CC=CO2)=N3)=O)=C(C(OCC)=O)C=N1 |
Myc-MAX dimerization
Mycro 3 is a potent and selective c-Myc inhibitor in whole cell assays, with weak inhibitory activity against Activator protein 1 (AP-1). Mycro 3 has a superior specificity profile to its predecessors. Mycro 3 inhibits the interaction between c-Myc and Max. Mycro 3 has high selectivity and inhibits c-Myc/Max dimerization and conjugation with DNA. Mycro 3 exhibits an excellent specificity with IC 50 s of 0.25 and 9.0 μM for cells with intact Myc alleles and Myc-null cells, respectively.
Mycro 3 (100 mg/kg; oral administration; daily for two months) induces marked shrinkage of pancreatic ductal adenocarcinoma (PDA), increases cancer cell apoptosis, and reduces cell proliferation. Tumor growth is also drastically attenuated in Mycro 3-treated NOD/SCID mice carrying orthotopic or heterotopic xenografts of human pancreatic cancer cells.
| Animal Model: | Moribund Pdx1-cre/KRAS * mice bearing pancreatic ductal adenocarcinoma (PDA) |
| Dosage: | 100 mg/kg |
| Administration: | Oral administration; daily for two months |
| Result: |
Increased survival time.
Mycro 3 administration was discontinued after two months, the mouse survived for an additional month. |
安全信息
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-100669 | 944547-46-0 Mycro 3 | 944547-46-0 | 1 mg | 486元 |
| 2026/06/05 | HY-100669 | 944547-46-0 Mycro 3 | 944547-46-0 | 5mg | 1116元 |